Research
E2F1 signatures stratify immunotherapy response and reveal YWHAQ vulnerability in esophageal squamous cell carcinoma
Nature ·
The Brief
- A study reports that E2F1 signatures can stratify immunotherapy response in esophageal squamous cell carcinoma.
- The study also reports a YWHAQ vulnerability in esophageal squamous cell carcinoma.
- Only the headline and feed listing were available; the full methods and results were not provided.
Why it matters
If E2F1 signatures reliably separate responders from non-responders to immunotherapy, they could inform patient selection in esophageal squamous cell carcinoma, though the provided sources do not give the supporting data.
Who’s affected
- cancer researchers
- oncologists studying immunotherapy biomarkers
- #esophageal cancer
- #immunotherapy
- #e2f1
- #ywhaq
- #biomarkers
Timeline
Listed in nature.com biological sciences subject feed
Biological sciences : nature.com subject feeds
E2F1 signatures stratify immunotherapy response and reveal YWHAQ vulnerability in esophageal squamous cell carcinoma